Perrone, E.; Calcagni, M.L.; Leccisotti, L.; Moretti, R.; Ghai, K.; Eismant, A.; Parkar, T.; Greifenstein, L.; Baum, R.P.
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. Cancers 2025, 17, 3070.
https://doi.org/10.3390/cancers17183070
AMA Style
Perrone E, Calcagni ML, Leccisotti L, Moretti R, Ghai K, Eismant A, Parkar T, Greifenstein L, Baum RP.
Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. Cancers. 2025; 17(18):3070.
https://doi.org/10.3390/cancers17183070
Chicago/Turabian Style
Perrone, Elisabetta, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Kriti Ghai, Aleksandr Eismant, Tanay Parkar, Lukas Greifenstein, and Richard Paul Baum.
2025. "Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival" Cancers 17, no. 18: 3070.
https://doi.org/10.3390/cancers17183070
APA Style
Perrone, E., Calcagni, M. L., Leccisotti, L., Moretti, R., Ghai, K., Eismant, A., Parkar, T., Greifenstein, L., & Baum, R. P.
(2025). Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival. Cancers, 17(18), 3070.
https://doi.org/10.3390/cancers17183070